Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1261734/000165495417002402/aols_8k.htm
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1261734/000165495417002402/aols_8k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aeolus Pharmaceuticals, Inc..
Aeolus Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:
Ticker: AOLSEvents:
CIK: 1261734
Form Type: 8-K Corporate News
Accession Number: 0001654954-17-002402
Submitted to the SEC: Fri Mar 24 2017 11:50:24 AM EST
Accepted by the SEC: Fri Mar 24 2017
Period: Friday, March 24, 2017
Industry: Pharmaceutical Preparations